TURKU, Finnland--(BUSINESS WIRE)--Medicortex Finland Oy (www.medicortex.fi), meldete heute den Erhalt von 1,1 Millionen US-Dollar an Forschungszuschüssen des US-amerikanischen Verteidigungsministeriums. Die Zuschüsse dienen der Förderung der klinischen Weiterentwicklung des Diagnose-Kits ProbTBITM unseres Unternehmens zur raschen Erkennung eines leichten Schädel-Hirn-Traumas und einer Gehirnerschütterung. Der Erhalt dieser hart umkämpften Zuschüsse ist ein deutliches Signal und die Anerkennung
Wed Jul 03, 2019 22:02
TURKU, Finlande--(BUSINESS WIRE)--Medicortex Finland Oy (www.medicortex.fi), a annoncé aujourd'hui l'octroi d'une subvention de 1,1 million de dollars du département américain de la Défense. La subvention finance le développement clinique continu du kit de diagnostic de la société, ProbTBITM , visant à détecter rapidement des lésions cérébrales traumatiques et des commotions cérébrales légères. Avoir remporté cette subvention hautement concurrentielle donne également un signe fort ainsi qu'une
Wed Jul 03, 2019 21:22
SASKATOON, Saskatchewan--(BUSINESS WIRE)--ZYUS Life Sciences Inc. (“ZYUS”) announced today that it has entered into a definitive agreement to acquire the Kentucky-based healthcare technology company Revon Systems, Inc. (“Revon”) in a share for share transaction. The closing date contemplated in the definitive agreement is July 31, 2019 or such other date as may be mutually agreed to between the parties, subject to the terms and conditions of the definitive agreement. ZYUS, which is focused on t
Wed Jul 03, 2019 20:45
TURKU, Finlandia--(BUSINESS WIRE)--Medicortex Finland Oy (www.medicortex.fi) ha oggi annunciato di aver ricevuto un finanziamento da 1,1 milioni di dollari USA dal Dipartimento della difesa degli Stati Uniti. Questa sovvenzione consentirà di finanziare lo sviluppo clinico continuativo del kit diagnostico ProbTBITM dell'azienda per il rilevamento rapido di lesioni e concussioni cerebrali traumatiche di lieve entità. La concessione di questo finanziamento estremamente competitivo rappresenta inol
Wed Jul 03, 2019 20:25
BOSTON--(BUSINESS WIRE)--ULTOMIRIS® (ravulizumab) Receives Marketing Authorization from European Commission for Adults with Paroxysmal Nocturnal Hemoglobinuria (PNH)
Wed Jul 03, 2019 20:00
LOS ANGELES--(BUSINESS WIRE)--Puma Biotechnology, Inc. (Nasdaq: PBYI), a biopharmaceutical company, presented updated interim results from the biliary cancer cohort of SUMMIT, an ongoing Phase II basket trial examining the efficacy of neratinib in HER2-mutated cancers, at the European Society for Medical Oncology (ESMO) 21st World Congress on Gastrointestinal Cancer 2019, currently taking place in Barcelona, Spain. “Treating HER2-mutant Biliary Tract Cancer with Neratinib: Benefits of HER2-dire
Wed Jul 03, 2019 19:10
TURKU, Finland--(BUSINESS WIRE)--Medicortex Finland Oy (www.medicortex.fi) heeft vandaag de toekenning bekendgemaakt van een subsidie van 1,1 miljoen dollar van het Amerikaanse ministerie van Defensie. De subsidie biedt financiering voor de verdere klinische ontwikkeling van de diagnostische set ProbTBITM van het bedrijf, voor snelle detectie van mild traumatisch hersenletsel en van hersenschuddingen. Het winnen van deze zeer concurrerende beurs is ook een sterk signaal en een erkenning van de
Wed Jul 03, 2019 14:49
TURKU, Finlandia--(BUSINESS WIRE)--Medicortex Finland Oy (www.medicortex.fi), ha anunciado la concesión de una subvención de 1,1 millón de dólares del Ministerio de Defensa de EE. UU. La subvención ofrece financiación para el desarrollo clínico continuado del kit de diagnóstico ProbTBITM de la empresa para la detección rápida de lesiones y conmociones cerebrales traumáticas leves. La obtención de esta codiciada subvención es también una sólida señal y reconocimiento del enfoque de Medicortex en
Wed Jul 03, 2019 14:48
TURKU, Finland--(BUSINESS WIRE)--Medicortex Finland Oy (www.medicortex.fi), today announced the award of a 1.1 million dollars grant from the USA Department of Defense. The grant provides funding for continued clinical development of the company’s diagnostic kit ProbTBITM for rapid detection of mild traumatic brain injury and concussion. Winning this highly competitive grant is also a strong signal and recognition of Medicortex’ approach for the urgent need to rapidly and reliably diagnose mild
Wed Jul 03, 2019 14:00
CAMBRIDGE, Mass. & OSAKA, Japan--(BUSINESS WIRE)--Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”), the global biotechnology leader in rare diseases, will present research covering a broad range of rare bleeding disorders at the 27th Annual International Society on Thrombosis and Haemostasis Congress (ISTH), July 6-10, 2019 in Melbourne, Australia. Showcased in 10 oral presentations and 38 poster presentations, these data underscore Takeda’s pursuit of treatment innovation...
Wed Jul 03, 2019 14:00
LONDON--(BUSINESS WIRE)--ViiV Healthcare, the global specialist HIV company, majority owned by GlaxoSmithKline, with Pfizer Inc. and Shionogi Limited as shareholders, today announced that the European Commission has granted Marketing Authorisation for Dovato (dolutegravir/lamivudine) for the treatment of HIV-1 infection in adults and adolescents above 12 years of age weighing at least 40 kg, with no known or suspected resistance to the integrase inhibitor class, or lamivudine.1 Deborah Waterhou
Wed Jul 03, 2019 11:19
スイス・ラーヘン--(BUSINESS WIRE)--（ビジネスワイヤ） -- オクタファルマの血液疾患関連ポートフォリオに関する新しい科学データが、来る2019年7月6～10日にオーストラリアのメルボルンで開催される第27回国際血栓止血学会（ISTH）総会で発表します。 5件のアブストラクトが総会でのポスター発表を受理されました。発表には、インヒビターを持つ重症血友病A患者におけるインヒビター根絶のためのNuwiq®（シモクトコグアルファ）またはoctanate®や、フォン・ヴィレブランド病患者での予防療法としてのwilate®の実臨床での経験から得たデータが含まれます。さらに2件の新しい研究のデザインと現状について発表します。Protect-NOW試験は治療歴がないか最小限度の治療しか受けていない血友病A患者で実生活環境におけるFVIIIの使用を検討し、MOTIVATE試験はインヒビター保有血友病A患者で、「標準治療」のITIを、FVIIIとエミシズマブを併用した新規ITIアプローチや、エミシズマブ予防療法のみと比較して安全性と有効性の証拠を取るものです。 いずれのアブストラクト
Wed Jul 03, 2019 09:09
瑞士拉亨--(BUSINESS WIRE)--(美國商業資訊) -- Octapharma血液產品陣容的新科學資料將在2019年7月6日至10日於澳洲墨爾本召開的國際血栓暨凝血學會(ISTH)第27屆大會上發表。 五篇摘要已被大會接受進行壁報展示。展示內容包括來自於Nuwiq® (simoctocog alfa)或octanate®用於帶有抑制抗體的嚴重A型血友病患者根除抑制抗體，以及wilate®作為類血友病(von Willebrand disease)患者預防性治療之實際經驗的數據。此外將發表兩項新研究的設計和目前狀態：Protect-NOW研究調查真實生活環境中 FVIII用於以往未曾治療和接受最少治療的A型血友病患者，MOTIVATE研究將記載和比較「標準療法」ITI與新型ITI方法（FVIII結合emicizumab）或單獨使用emicizumab預防性治療對於帶有抑制抗體的A型血友病患者的安全性和有效性。 所有摘要均在ISTH網站(https://www.isth.org/news/457341/ISTH-2019-Abstracts-Now-Available-Onl
Wed Jul 03, 2019 09:05
OSS, Netherlands--(BUSINESS WIRE)--Citryll completes first closing of a € 15M Series A to develop its NETosis inhibiting therapeutic antibody
Wed Jul 03, 2019 09:05
瑞士拉亨--(BUSINESS WIRE)--(美国商业资讯) -- Octapharma血液产品阵容的新科学数据将在2019年7月6日至10日澳大利亚墨尔本召开的国际血栓和瘀血学会(ISTH)第27届大会上呈报。 5篇摘要已被大会接受进行壁报呈报。上述呈报包括Nuwiq® (simoctocog alfa)或octanate®用于伴抑制因子的重症血友病A患者清除抑制因子以及wilate®作为von Willebrand病患者预防性治疗的真实世界经验。此外将呈报两项新研究的设计和当前状态：Protect-NOW研究调查真实生活环境中 FVIII用于既往未曾治疗和最少治疗的血友病A患者，MOTIVATE研究将记载和比较“标准治疗”ITI与新ITI方法（FVIII联合emicizumab）或emicizumab单药预防性治疗用于伴抑制因子的血友病A患者的安全性和有效性。 所有摘要均发布于ISTH网站(https://www.isth.org/news/457341/ISTH-2019-Abstracts-Now-Available-Online.htm)。壁报标题、呈报日期和时间如下：
Wed Jul 03, 2019 09:01
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced that the Phase III MINISTONE-2 study met its primary endpoint, demonstrating that XOFLUZA™ (baloxavir marboxil) was well-tolerated in children with the flu. The study also showed that XOFLUZA is comparable to oseltamivir – a proven effective treatment for children with the flu – at reducing the duration of flu symptoms, including fever. The study assessed XOFLUZA ve
Wed Jul 03, 2019 08:00
CHAPEL HILL, N.C.--(BUSINESS WIRE)--The Neuroscience of Autism: New Clues for How the Condition Begins
Tue Jul 02, 2019 22:25
LACHEN, Svizzera--(BUSINESS WIRE)--Nuovi dati scientifici nel portafoglio di ematologia di Octapharma saranno presentati al prossimo 27° Congresso della International Society on Thrombosis and Haemostasis (ISTH), che si svolgerà a Melbourne, in Australia, dal 6 al 10 luglio 2019. Sono stati accettati cinque abstract per presentazioni poster al Congresso. Le presentazioni comprendono dati ricavati da esperienze reali con Nuwiq® (simoctocog alfa) o octanate® per l'eradicazione di inibitori nei pa
Tue Jul 02, 2019 21:09
LACHEN, Suisse--(BUSINESS WIRE)--De nouvelles données scientifiques concernant le portefeuille Hématologie d’Octapharma seront présentées à l’occasion de la 27e édition du congrès de la Société internationale de thrombose et d’hémostase (ISTH) qui aura lieu à Melbourne, en Australie, du 6 au 10 juillet 2019. Cinq résumés ont été acceptés pour des présentations d’affiches au congrès. Les présentations incluent des données issues de l’expérience concrète avec Nuwiq® (simoctocog alfa) ou octanate®
Tue Jul 02, 2019 20:51
LACHEN, Schweiz--(BUSINESS WIRE)--Neue wissenschaftliche Daten aus dem Hämatologie-Portfolio werden auf dem kommenden 27. Congress of the International Society on Thrombosis and Haemostasis (ISTH) präsentiert, der vom 6. bis 10. Juli 2019 in Melbourne, Australien, stattfindet. Fünf Abstracts sind für die Posterpräsentation während des Kongresses zugelassen. Die Präsentationen beinhalten Daten aus Praxiserfahrungen mit Nuwiq® (Simoctocog alfa) oder Octanate® zur Hemmkörpereradikation bei Patient
Tue Jul 02, 2019 20:51
LACHEN, Suiza--(BUSINESS WIRE)--Durante el 27º Congreso de la Sociedad Internacional de Hemostasia y Trombosis (ISTH, por sus siglas en inglés) se presentarán nuevos datos científicos sobre la cartera de Hematología de Octapharma. El evento tendrá lugar en Melbourne, Australia, del 6 al 10 de julio de 2019. Se han aceptado cinco resúmenes para la presentación de pósters en el Congreso. Las presentaciones incluyen datos de experiencias reales con Nuwiq® (simoctocog alfa) u octanate® para la erra
Tue Jul 02, 2019 20:03
LACHEN, Suíça--(BUSINESS WIRE)--Novos dados científicos sobre o portfólio de Hematologia da Octapharma serão apresentados no próximo 27º Congresso da Sociedade Internacional sobre Trombose e Hemostasia (ISTH), que será realizado em Melbourne, Austrália, de 6 a 10 de julho de 2019. Foram aceitos cinco resumos para apresentação com pôsteres no congresso. As apresentações abrangem dados de experiências do mundo real com o Nuwiq® (simoctocog alfa) ou octanate® para erradicação do inibidor em pacien
Tue Jul 02, 2019 20:00
CHICAGO--(BUSINESS WIRE)--<a href="https://twitter.com/hashtag/MolBio?src=hash" target="_blank">#MolBio</a>--SnapGene supports conversion of Vector NTI® Express and Advance files and databases, streamlining the transition for legacy Vector NT
Tue Jul 02, 2019 17:00
STAMFORD, Conn.--(BUSINESS WIRE)--Julie Ducharme, BPharm, MSc, PhD Named Vice President and Chief Scientific Officer of Purdue Pharma L.P.
Tue Jul 02, 2019 15:30
NEW YORK--(BUSINESS WIRE)--<a href="https://twitter.com/hashtag/MDSO?src=hash" target="_blank">#MDSO</a>--Medidata (NASDAQ: MDSO) announced that TissueTech, Inc. has chosen the Medidata Rave Clinical Cloud™ as its end-to-end platform for clinical trials. TissueTech recognizes this partnership as critical to helping spearhead the company’s transformation in biologics with a focus on regenerative therapies derived from human birth tissue for patients with serious unmet clinical needs. TissueTech...
Tue Jul 02, 2019 15:30
BOTHELL, Wash.--(BUSINESS WIRE)--Seattle Genetics, Inc. (Nasdaq: SGEN) announced today that it will report its second quarter 2019 financial results on Tuesday, July 16, 2019 after the close of financial markets. Following the announcement, management will host a conference call and webcast discussion of the results and provide a general corporate update. Access to the event can be obtained as follows: LIVE access on Tuesday, July 16, 2019 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time Telepho
Tue Jul 02, 2019 15:00
CHARLOTTE, N.C.--(BUSINESS WIRE)--Premier Inc. (NASDAQ: PINC), through its ProvideGx™ program, is now supplying cysteine hydrochloride injection to providers, a critical drug for pediatric and adult patients that require total parenteral nutrition (TPN). Cysteine hydrochloride has been in shortage in the U.S. since 2015. This FDA-approved New Drug Application (NDA) for cysteine hydrochloride injection is held by Exela Pharma Sciences, LLC, a U.S.-based manufacturer. Current supplies of cysteine
Tue Jul 02, 2019 14:00
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Dicerna announced it submitted a CTA application to the Swedish MPA last week to conduct a first-in-human Phase 1/2 study of DCR-A1AT.
Tue Jul 02, 2019 14:00
LACHEN, Zwitserland--(BUSINESS WIRE)--Nieuwe wetenschappelijke gegevens over de Hematology-portefeuille van Octapharma zullen op het komende 27e congres van de International Society on Thrombosis and Haemostasis (ISTH) worden gepresenteerd. Het congres vindt plaats in Melbourne, in Australië, van 6 tot 10 juli 2019. Vijf abstracts zijn geaccepteerd voor posterpresentatie op het congres. De presentaties bevatten gegevens uit praktijkervaring met Nuwiq® (simoctocog alfa) of octanate® voor de uitr
Tue Jul 02, 2019 11:08
SANTA ANA, Calif.--(BUSINESS WIRE)--FUJIFILM Irvine Scientific, Inc., a global leader in the innovation, development, and manufacture of cell culture media, announced plans to open a third manufacturing facility located in Tilburg, Netherlands. The company currently has sites in the United States and Japan. Fujifilm’s investment in this project demonstrates its commitment to accelerate development in bioproduction and, cell and gene therapy markets. The facility will occupy a 250,000 square foo
Tue Jul 02, 2019 11:02
LACHEN, Switzerland--(BUSINESS WIRE)--New scientific data on Octapharma’s Haematology portfolio will be presented at the upcoming 27th Congress of the International Society on Thrombosis and Haemostasis (ISTH), taking place in Melbourne, Australia, from 6 to 10 July 2019. Five abstracts have been accepted for poster presentation at the Congress. The presentations include data from real-world experience with Nuwiq® (simoctocog alfa) or octanate® for inhibitor eradication in patients with severe
Tue Jul 02, 2019 10:38
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Dicerna announced the grant of inducement stock options to purchase a total of 529,500 shares of common stock to be distributed among 10 new employees
Mon Jul 01, 2019 23:30
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Foundation Medicine, Inc. today announced it has received approval from the U.S. Food and Drug Administration (FDA) for FoundationOne®CDx to be used as a companion diagnostic for LYNPARZA® (Olaparib) for first line maintenance therapy in BRCA-mutated advanced ovarian cancer. FoundationOne CDx is an FDA-approved comprehensive genomic profiling (CGP) test for all solid tumors that incorporates multiple companion diagnostics. FoundationOne CDx detects tumor BRCA1
Mon Jul 01, 2019 22:30
BRISBANE, Calif.--(BUSINESS WIRE)--Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, today announced the publication of a manuscript describing the activity of allele-selective zinc finger protein transcription-factors (ZFP-TFs) in preclinical models of Huntington’s disease (HD). The data were published online on July 1 and will appear in the July 2019 issue of Nature Medicine. The publication describes research by Sangamo and collaborators at the CHDI Foundation, in which
Mon Jul 01, 2019 18:00
NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE : PFE) a annoncé aujourd'hui la conclusion de son acquisition de la société privée de biotechnologie de stade clinique, Therachon Holding AG. Aux termes de cet accord, Pfizer fera l’acquisition de Therachon pour 340 millions de dollars, un paiement supplémentaire de 470 millions de dollars étant subordonné à la réalisation d'étapes clés du développement et de la commercialisation du TA-46, un médicament expérimental pour le traitement de l’achondropl
Mon Jul 01, 2019 17:37
NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) gab heute den erfolgreichen Abschluss der Akquisition des privaten klinisch forschenden Biotechnologieunternehmens Therachon Holding AG bekannt. Gemäss den die Transaktion betreffenden Bestimmungen akquirierte Pfizer Therachon für 340 Millionen US-Dollar mit Zusatzzahlungen in Höhe von 470 Millionen US-Dollar, die von der Erreichung wichtiger Meilensteine bei der Entwicklung und Vermarktung von TA-46, einem Prüfpräparat zur Behandlung von Achon
Mon Jul 01, 2019 17:37
NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) today announced the successful completion of its acquisition of the privately held clinical-stage biotechnology company Therachon Holding AG. Under the terms of the transaction, Pfizer acquired Therachon for $340 million with an additional $470 million in additional payments contingent on the achievement of key milestones in the development and commercialization of TA-46. TA-46 is an investigational medicine for the treatment of achondroplasia,
Mon Jul 01, 2019 17:00
BEERSE, Belgique--(BUSINESS WIRE)--Les sociétés pharmaceutiques Janssen de Johnson & Johnson ont annoncé aujourd'hui que le Comité des médicaments à usage humain (CHMP) de l'Agence européenne des médicaments (EMA) a recommandé l'extension de l'autorisation actuelle de mise sur le marché pour l'Imbruvica® (ibrutinib) pour deux indications. La première recommandation porte sur l'utilisation de l'ibrutinib en association avec l'obinutuzumab chez les patients adultes atteints d'une leucémie lym
Mon Jul 01, 2019 16:43
BEERSE, Belgien--(BUSINESS WIRE)--Wie die Janssen Pharmaceutical Companies of Johnson & Johnson heute bekannt gaben, hat der Ausschuss für Humanmedizin (CHMP) der Europäischen Arzneimittelagentur (EMA) die Erweiterung der bestehenden Marktzulassung für Imbruvica® (Ibrutinib) bei zwei Indikationen empfohlen. Eine Empfehlung gilt der Nutzung von Ibrutinib in Kombination mit Obinutuzumab zur Behandlung erwachsener Patienten mit bisher unbehandelter chronischer lymphatischer Leukämie (CLL).1 Di
Mon Jul 01, 2019 16:41
Δεν υπάρχουν σχόλια:
Δημοσίευση σχολίου